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Purpose:

To directly compare magnetic resonance (MR) imaging and computed tomography (CT) parametric response map (PRM) measurements of gas trapping and emphysema in ex-smokers both with
and without chronic obstructive pulmonary disease (COPD).

Materials and
Methods:

Participants provided written informed consent to a protocol that
was approved by a local research ethics board and Health Canada
and was compliant with the HIPAA (Institutional Review Board
Reg. #00000940). The prospectively planned study was performed
from March 2014 to December 2014 and included 58 ex-smokers
(mean age, 73 years 6 9) with (n = 32; mean age, 74 years 6 7)
and without (n = 26; mean age, 70 years 6 11) COPD. MR imaging
(at functional residual capacity plus 1 L), CT (at full inspiration and
expiration), and spirometry or plethysmography were performed
during a 2-hour visit to generate ventilation defect percent (VDP),
apparent diffusion coefficient (ADC), and PRM gas trapping and
emphysema measurements. The relationships between pulmonary function and imaging measurements were determined with
analysis of variance (ANOVA), Holm-Bonferroni corrected Pearson correlations, multivariate regression modeling, and the spatial
overlap coefficient (SOC).

Results:

VDP, ADC, and PRM gas trapping and emphysema (ANOVA, P ,
.001) measurements were significantly different in healthy ex-smokers
than they were in ex-smokers with COPD. In all ex-smokers, VDP
was correlated with PRM gas trapping (r = 0.58, P , .001) and with
PRM emphysema (r = 0.68, P , .001). VDP was also significantly
correlated with PRM in ex-smokers with COPD (gas trapping: r =
0.47 and P = .03; emphysema: r = 0.62 and P , .001) but not in
healthy ex-smokers. In a multivariate model that predicted PRM gas
trapping, the forced expiratory volume in 1 second normalized to the
forced vital capacity (standardized coefficients [bS] = 20.69, P = .001)
and airway wall area percent (bS = 20.22, P = .02) were significant
predictors. PRM emphysema was predicted by the diffusing capacity
for carbon monoxide (bS = 20.29, P = .03) and VDP (bS = 0.41, P =
.001). Helium 3 ADC values were significantly elevated in PRM gastrapping regions (P , .001). The spatial relationship for ventilation
defects was significantly greater with PRM gas trapping than with
PRM emphysema in patients with mild (for gas trapping, SOC = 36%
6 28; for emphysema, SOC = 1% 6 2; P = .001) and moderate (for
gas trapping, SOC = 34% 6 28; for emphysema, SOC = 7% 6 15; P =
.006) COPD. For severe COPD, the spatial relationship for ventilation
defects with PRM emphysema (SOC = 64% 6 30) was significantly
greater than that for PRM gas trapping (SOC = 36% 6 18; P = .01).

Conclusion:

In all ex-smokers, ADC values were significantly elevated in regions of PRM gas trapping, and VDP was quantitatively and spatially related to both PRM gas trapping and PRM emphysema. In
patients with mild to moderate COPD, VDP was related to PRM
gas trapping, whereas in patients with severe COPD, VDP correlated with both PRM gas trapping and PRM emphysema.

An earlier incorrect version of this article appeared online. This article was
corrected on January 12, 2016.
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C

hronic obstructive pulmonary
disease (COPD) is characterized
by persistent airflow limitation

Advances in Knowledge
nn In 58 ex-smokers with (n = 32)
and without (n = 26) chronic obstructive pulmonary disease
(COPD), 3He MR imaging ventilation defect percent (VDP) was
significantly correlated with inspiratory and expiratory CT parametric response map (PRM) measurements of gas trapping (r = 0.58, P
, .001) and emphysema (r = 0.68,
P , .001); 3He apparent diffusion
coefficient (ADC) values were also
significantly correlated with PRM
gas trapping (r = 0.55, P , .001)
and PRM emphysema (r = 0.62, P
, .001).

nn In a significant multivariate model

that predicted PRM gas trapping,
the forced expiratory volume in 1
second normalized to the forced
vital capacity (standardized coefficient [bS] = 20.69, P = .001) and
airway wall area percent (bS =
20.22, P = .02) were significant
predictors, whereas PRM emphysema was predicted by MR imaging VDP (bS = 0.41, P = .001)
and diffusing capacity for carbon
monoxide (bS = 20.29, P = .03).

nn In all ex-smokers, spatial CT and

MR imaging relationships showed
that 3He MR imaging ADC values
were significantly elevated in regions
of PRM gas trapping (P , .001).

nn In patients with mild (for gas trapping, spatial overlap coefficient
[SOC] = 36% 6 28; for emphysema, SOC = 1% 6 2; P = .001)
and moderate (for gas trapping,
SOC = 34% 6 28; for emphysema, SOC = 7% 6 15; P = .006)
COPD (n = 25), 3He MR imaging
ventilation defects were quantitatively and spatially related to PRM
gas trapping, whereas in patients
with severe COPD (n = 7), MR
imaging ventilation defects were
quantitatively and spatially related
to both PRM gas trapping and
emphysema (for gas trapping,
SOC = 36% 6 18; for emphysema, SOC = 64% 6 30; P = .01).
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related to airway remodeling, inflammation, and emphysematous destruction
(1). These pathophysiologic features can
be regionally quantified by using highresolution x-ray computed tomography
(CT) measurements of the airways and
parenchyma (2–5). For example, airways disease can be estimated by using
CT measurements of airway wall area
percent and lumen area, whereas emphysema may be estimated by using CT
attenuation thresholds, such as 2950
HU or the 15th percentile value from
inspiratory CT (4,6). The expiratory
CT attenuation-histogram threshold of
–856 HU also provides a way to estimate
gas trapping, reflecting the longer time
constants for emptying the parenchyma
via obstructed airways (7).
Recently,
parametric
response
mapping (PRM) was used to evaluate
COPD, breast cancer treatment response, and osteoporosis (8–11). In patients with COPD, coregistered inspiratory and expiratory thoracic CT can
be evaluated by using well-established
attenuation thresholds, resulting in
the classification of healthy, emphysematous, and gas-trapping lung regions
(9,12). However, the relationship of
PRM-classified tissue with other established measurements of airways disease
and emphysema is not well understood.
Very recently, PRM phenotyping was

Implications for Patient Care
nn In ex-smokers with mild (P =
.001) and moderate (P = .006)
COPD, regions of PRM gas trapping were spatially and quantitatively related to MR imaging ventilation abnormalities, whereas in
patients with severe COPD, ventilation abnormalities were related to both PRM gas trapping
(P = .009) and PRM emphysema
(P = .01).
nn While 3He MR imaging is unlikely
to be translated clinically, this
information may be used to help
better understand PRM gas trapping measurements, which may
be more widely adopted for clinical phenotyping in patients with
COPD.

used to differentiate among current
and former smokers with and without
COPD, but the clinical relevance and
cause of PRM measurements of airways
disease is uncertain (13).
Single photon emission computed
tomography and positron emission tomography have also been used to depict
pulmonary function abnormalities in patients with COPD (14,15). In addition,
hyperpolarized inhaled noble gas MR imaging with helium 3 (3He) and xenon 129
gases, as well as oxygen-enhanced and
fluorine 19 magnetic resonance (MR)
imaging, provide other ways to quantify
both functional and structural pulmonary biomarkers of COPD (16–19). Hyperpolarized 3He MR imaging apparent
diffusion coefficients (ADCs) reflect the
size of the lung acinar units. Such values
are abnormally elevated in smokers with
and without COPD (20,21). 3He MR imaging ventilation defects may reflect both
airways disease and emphysema in patients with advanced COPD, but in mild
COPD and asthma, ventilation defects
reflect airways disease (22,23). Despite
the potential of 3He MR imaging, limited
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and unpredictable global quantities and
high cost have hampered clinical translation. We wanted to determine the quantitative and spatial relationships of PRM
gas trapping and PRM emphysema measurements with MR imaging measurements of parenchymal tissue integrity
(ie, ADC) and ventilation because these
are clinically important imaging findings
and phenotypes of COPD. Thus, our objective was to directly compare MR imaging and CT PRM measurements of gas
trapping and emphysema in ex-smokers
with and without COPD.

Materials and Methods
Study Volunteers
Participants provided written informed
consent to a protocol that was approved
by a local research ethics board and
Health Canada and that was compliant
with the Health Insurance Portability and
Accountability Act (Institutional Review
Board Reg.#00000940). The study was
prospectively planned and performed
from March 2014 to December 2014.
MR Imaging
Acquisition of conventional proton (hydrogen 1 [1H]), 3He static ventilation,
and 3He diffusion-weighted MR images
was performed with a whole-body 3-T
Discovery MR750 system (GE Healthcare, Milwaukee, Wis), as was previously described (24). Polarization (Polarean; HeliSpin, Durham, NC) was
achieved to 40%, and the magnetized
gas was diluted with medical-grade nitrogen 2 (N2) gas to a level of 5 mL per
kilogram of body weight. Coronal images (multisection, with no gaps) were
acquired with breath holding from
functional residual capacity after subjects inhaled a 1-L gas mixture (helium
4 and N2 for 1H MR imaging and 3He
and N2 for 3He MR imaging). Hydrogen 1 MR imaging was performed with
a whole-body radiofrequency coil and
a fast spoiled gradient-recalled-echo
sequence with a partial echo and the
following parameters: total acquisition
time, 12 sec; repetition time msec/echo
time msec, 4.3/1.0; flip angle, 30°; field
of view, 40 3 40 cm; matrix, 128 3 80
Radiology: Volume 279: Number 2—May 2016

n

(zero padded to 128 3 128); partialecho percent, 62.5%; bandwidth, 62.50
kHz; one excitation; 14 sections; section thickness, 15 mm; zero gap.
3
He static ventilation MR images
were acquired by using a fast spoiled
gradient-recalled-echo method with a
partial echo and the following parameters: total acquisition time, 10 sec;
3.8/1.0; flip angle, 7°; field of view,
40 3 40 cm; matrix, 128 3 80 (zeropadded to 128 3 128); partial-echo
percent, 62.5%; bandwidth, 62.50
kHz; one excitation; 14 sections; section thickness, 15 mm; zero gap. 3He
diffusion-weighted MR images were
also acquired by using fast spoiled gradient-recalled-echo sequence with centric k-space sampling and the following
parameters: total acquisition time, 14
sec; 6.8/4.5; flip angle, 8°; field of view,
40 3 40 cm; matrix, 128 3 128; bandwidth, 62.50 kHz; one excitation; seven
sections; section thickness, 30 mm;
zero gap. Two interleaved images were
also acquired, both with and without
additional diffusion sensitization and
the following parameters: 1.94 G/cm;
b = 1.6 sec/cm2; rise and fall time, 0.5
msec; gradient duration, 0.46 msec;
diffusion time, 1.46 msec.

CT Imaging
As was previously described, CT images were acquired with subjects in the
supine position approximately 10 minutes before MR imaging and 1 hour
after administration of salbutamol. A
64-section Lightspeed VCT imager (GE
Healthcare, Milwaukee, Wis) was used
to acquire breath-hold images at full
inspiration and full expiration by using
a spiral acquisition approach and the
following parameters: detector configuration, 64 3 0.625 mm; peak voltage,
120 kVp; effective current, 100 mA; rotation time, 500 msec; pitch, 1.0; section thickness, 1.25 mm; number of sections, 200–250, depending on patient
size; matrix, 512 3 512 (25). CT data
were reconstructed by using a standard
convolution kernel to 1.25 mm. The ImPACT CT patient dosimetry calculator
(http://www.impactscan.org/ctdosimetry.htm), which is based on the United Kingdom Health Protection Agency

radiology.rsna.org
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NRPB-SR250, and our manufacturer
settings were used to calculate total
effective dose (1.8 mSv for inspiration
and 1.4 mSv for expiration). For inspiration CT, size-specific dose estimate
was calculated to be 5–9 mGy on the
basis of volumetric CT dose index of 4.4
mGy, total effective dose of 1.8 mSv,
and size-dependent conversion factor of
1.00–2.00, an approach used by Christener et al (26,27). For expiration CT,
the size-specific dose estimate was 3–7
mGy on the basis of volumetric CT dose
index of 3.3 mGy, total effective dose
of 1.4 mSv, and size-dependent conversion factor of 1.00–2.00.

MR Image Analysis
As was previously described, 3He MR
imaging semiautomated segmentation
was performed by a single observer
(D.P., with 3 years of experience) to
generate ventilation defect percent
(VDP), with the ventilation defect volume normalized to 1H MR imaging thoracic cavity volume (28). A detailed description of this process is provided in
Appendix E1(online).
CT Image Analysis
CT images were analyzed with Pulmonary Workstation 2.0 (VIDA Diagnostics, Coralville, IA) by a single observer
(D.P.I.C.,with 2 years of experience)
to measure wall area percent and segment the lung regions. These analyses
are fully automated, as was previously
described and validated (29,30). The
relative area of the CT attenuation histogram of less than 2950 HU and 2856
HU at inspiratory and expiratory CT,
respectively, were determined by using
MATLAB (Mathworks, Natick, Mass).
Briefly, pulmonary PRM results can
be generated by coregistering inspiratory and expiratory CT images and
classifying voxels on the basis of their
specific thresholds into healthy, gastrapping, or emphysema tissue components. The specific details of this process
are given in Appendix E1 (online).
Statistics
Analysis of variance was performed
with post hoc analysis and Tukey correction to determine differences in
599
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Table 1
Subject Demographics

Characteristic
Age (y)
No. of male subjects
Body mass index (kg/m2)
Smoking history (pack-years)
FEV1*
FEV1/FVC (%)
Total lung capacity*
Inspiratory capacity*
Residual volume*
DLCO*

Ex-smokers with COPD

Healthy
Ex-Smokers
(n = 26)

All
(n = 32)

GOLD I
(n = 12)

GOLD II
(n = 13)

GOLD III/IV
(n = 7)

P Value

70 6 11
15
30 6 4
28 6 16
103 6 19
80 6 7
96 6 13
103 6 23
100 6 21
89 6 18§

74 6 7
25
26 6 3
43 6 26
73 6 27
55 6 11
110 6 16†
91 6 27
140 6 39
68 6 23†

75 6 8
11
26 6 3
31 6 17
101 6 14
63 6 4
103 6 34‡
100 6 23
123 6 16
73 6 29‡

74 6 8
9
27 6 3
50 6 28
64 6 10
55 6 8
106 6 17
94 6 32
134 6 33
66 6 24

73 6 6
5
26 6 4
51 6 30
39 6 7
40 6 5
115 6 20
70 6 10
180 6 53
51 6 15

.104
…
,.001
.012
,.001
,.001
,.001
.078
,.001
,.001

Note.—Unless otherwise indicated, data are mean plus or minus standard deviation. P values were determined by analysis of variance with Tukey correction.
* Percent of predicted value.
†

n = 31.

‡

n = 11.

§

n = 25.

participant characteristics and imaging
measurements by using SPSS Statistics
V22.0 (SPSS, Chicago, Ill). Pearson
correlation coefficients were determined for MR imaging, and PRM measurements were adjusted with HolmBonferroni correction. The agreement
between CT PRM and 3He MR imaging
measurements was evaluated with the
Bland-Altman method and GraphPad
Prism V6.0 (GraphPad Software, La
Jolla, Calif). Multivariate regression
models for both PRM gas trapping and
PRM emphysema were determined
with the step-wise method; variables
were added to the model when P , .15
and removed when P  .15 by using
SPSS software.

Results
Participant Characteristics
Table 1 shows demographic characteristics and pulmonary function measurements for 58 participants (mean
age, 73 years 6 9), including 26 exsmokers with normal spirometry results (mean age, 70 years 6 11) and
32 ex-smokers with COPD (mean age,
74 years 6 7). Patient subgroups were
significantly different with respect to
600

body mass index (P , .001), smoking
history (pack-years, P = .01), forced
expiratory volume in 1 second (FEV1,
P , .001), FEV1 normalized to the
forced vital capacity (FEV1/FVC, P ,
.001), and diffusing capacity for carbon monoxide (DLCO, P , .001), but
not age (P = .1).

Qualitative Ventilation and PRM Results
Figure 1 shows MR and CT images in
a representative ex-smoker with no airflow limitation and three ex-smokers
with COPD. In the two ex-smokers with
more advanced COPD (an 84-year-old
man with Global Initiative for Chronic
Obstructive Lung Disease [GOLD] grade
II; FEV1, 52% of predicted value; FEV1/
FVC, 44%; and a 67-year-old woman
with GOLD III disease; FEV1, 33%
of predicted value; FEV1/FVC, 39%),
more pronounced 3He ventilation defects; a greater number of PRM voxels,
a finding reflective of emphysema; and
elevated ADC values were present. Alternatively, in two ex-smokers with mild
or no disease (a 55-year-old man with
FEV1, 83% of predicted value and FEV1/
FVC, 77% and a 69-year-old man with
GOLD I disease; FEV1, 89% of predicted
value; FEV1/FVC, 69%), more homogeneous ventilation and a greater number

of PRM voxels were present, findings reflective of normal or healthy tissue.

Ventilation and PRM Measurements by
GOLD Severity
Table 2 summarizes the measurements
for MR imaging ventilation and emphysema and for CT-derived gas trapping,
emphysema, and PRM measurements. In
ex-smokers with COPD, VDP (P , .001),
ADC (P , .001), relative area of the CT
attenuation histogram of less than 2950
HU (P , .001), PRM gas trapping (P ,
.001), and emphysema (P , .001) were
significantly greater than in ex-smokers
with no airflow limitation. There were no
significant differences in CT airway measurement of wall area percent (P = .9).
Figure 2 shows that VDP was significantly
different between healthy ex-smokers
(8% 6 4) and ex-smokers with moderate (GOLD II, 20% 6 11, P , .001) to
severe (GOLD III/IV, 37% 6 9, P , .001)
COPD, but not in ex-smokers with mild
COPD (GOLD I, 11% 6 6, P = .5). VDP
was also significantly different between
those with GOLD I and GOLD II disease
(P = .04), those with GOLD II and GOLD
II/IV disease (P , .001), and those with
GOLD I and GOLD III/IV disease (P ,
.001). PRM measurements were significantly different for healthy ex-smokers
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Figure 1

Figure 1: Ventilation and PRM in a 55-year-old man without COPD (FEV1, 83% of predicted value; FEV1/FVC, 77%;
residual volume to total lung capacity ratio [RV/TLC], 45%), a 69-year-old man with GOLD I disease (FEV1, 89% of predicted value; FEV1/FVC, 69%; RV/TLC, 39%; DLCO, 67% of predicted value), an 84-year-old man with GOLD II disease
(FEV1, 52% of predicted value; FEV1/FVC, 44%; RV/TLC, 62%; DLCO, 47% of predicted value), and a 67-year-old woman
with GOLD III disease (FEV1, 33% of predicted value; FEV1/FVC, 39%; RV/TLC, 72%; DLCO, 28% of predicted value). First
row: 3He MR images coregistered with 1H MR images (grayscale) show static ventilation (blue areas). Second row:
3
He MR imaging ADC maps show that the ex-smokers with more advanced COPD (GOLD II/III disease) have elevated
ADC values. Third row: CT attenuation masks show areas of less than 2950 HU (yellow areas). Fourth row: PRMs show
areas of healthy tissue (green), gas trapping (yellow), and emphysema (red).

(gas trapping, 13% 6 10; emphysema,
0.5% 6 0.5) and those with moderate
(GOLD II: gas trapping, 27 6 14%, P =
.003; emphysema, 8 6 11%, P = .003)
to severe (GOLD III/IV: gas trapping,
41 6 8%, P , .001; emphysema, 13 6
12%, P , .001) COPD. PRM gas trapping was significantly different between
ex-smokers and those with mild COPD
Radiology: Volume 279: Number 2—May 2016
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(GOLD I, 31% 6 11, P , .001). PRM
emphysema was significantly different
between those with GOLD I and GOLD
III/IV disease (P = .03). ADC values
were significantly different between
healthy ex-smokers (0.29 cm2/s 6 0.08)
and those with GOLD II (0.36 cm2/s 6
0.06, P = .02) and GOLD III/IV (0.41 6
0.05 cm2/s, P , .001) disease, but not

radiology.rsna.org

those with GOLD I disease (0.34 cm2/s
6 0.03, P = .2).

Relationships for MR Imaging and PRM
Measurements
Tables 3 and 4 show the Holm-Bonferroni-corrected Pearson correlations and
multivariate regression model results
for CT-derived PRM gas trapping and
601
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Table 2
Imaging Measurements

Measurement

Healthy
Ex-Smokers
(n = 26)

Ex-smokers with COPD
All
(n = 32)

GOLD I
(n = 12)

GOLD II
(n = 13)

GOLD III/IV
(n = 7)

P Value

CT
RA950 (%)
RA856 (%)
6G wall area percent (%)
3
He MR imaging
Ventilation (%)
VDP (%)
ADC (cm2/sec)
PRM
Healthy (%)
Gas trapping (%)
Emphysema (%)

261
14 6 10
65 6 2

10 6 9
37 6 18
65 6 2

664
34 6 13
65 6 2

10 6 10
35 6 20
66 6 2

15 6 12
53 6 16
66 6 2

,.001
,.001
.882

92 6 4
8 6 4*
0.29 6 0.08*

20 6 13
12 6 4
0.36 6 0.06†

88 6 6
12 6 6
0.34 6 0.03‡

80 6 11
20 6 11
0.36 6 0.06§

63 6 9
37 6 9
0.41 6 0.05

,.001
,.001
,.001

85 6 11
13 6 10
0.5 6 0.5

60 6 18
31 6 12
7 6 10

64 6 13
31 6 11
363

63 6 20
27 6 14
8 6 11

46 6 17
41 6 9
13 6 12

,.001
,.001
.001

Note.—Data are mean plus or minus standard deviation. P values were determined by analysis of variance with Tukey correction. RA950 = relative area of the lung with attenuation values less than
2950 HU at inspiration CT, RA856 = relative area of the lung with attenuation values less than 2856 HU at expiration CT, 6G = sixth-generation airway.
* n = 24.
†

n = 30.

‡

n = 11.

§

n = 12.

emphysema measurements. In ex-smokers with COPD only, PRM gas trapping
was significantly related to FEV1/FVC (r
= 20.58, P = .003), ADC (r = 0.53, P =
.01), and VDP (r = 0.47, P = .03). PRM
emphysema was significantly correlated
with FEV1 (r = 20.43, P = .03), FEV1/
FVC (r = 20.52, P = .008), DLCO (r =
20.69, P , .001), ADC (r = 0.69, P ,
.001), and VDP (r = 0.62, P , .001) in
ex-smokers with COPD. Figure 3 shows
linear regressions for PRM gas trapping
and emphysema and shows that VDP
was significantly correlated with PRM
gas trapping (r = 0.58, P , .001) and
PRM emphysema (r = 0.68, P , .001)
in all subjects and in ex-smokers with
COPD (gas trapping: r = 0.47, P = .03;
emphysema: r = 0.62, P , .001), but
not in healthy ex-smokers. ADC was
also significantly correlated with PRM
gas trapping (r = 0.55, P , .001) and
PRM emphysema (r = 0.62, P , .001)
in all subjects and in ex-smokers with
COPD (gas trapping: r = 0.53, P = .01;
emphysema: r = 0.69, P , .001), but
not in healthy ex-smokers. Figure 3 also
shows Bland-Altman plots for PRM gas
trapping and emphysema. In relation to
602

VDP, there was a negative bias for PRM
gas trapping (29% 6 12; 95% confidence interval: 232%,15%) and a positive bias for PRM emphysema (11% 6
9; 95% confidence interval: 26%, 28%).
Table 4 shows that, in the multivariate
regression model that explains PRM gas
trapping, FEV1/FVC (standardiced coefficient [bS] = 20.69, P = .001) and wall
area percent (bS = 20.22, P = .02) make
significant contributions, whereas, for
the PRM emphysema model, DLCO (bS =
20.29, P = .03) and VDP (bS = 0.41, P =
.001) were significant.

Spatial and Regional Relationships
Given the significant quantitative relationships between MR imaging and
PRM COPD measurements, we evaluated the spatial correlations of ventilation defects with PRM measurements.
Qualitative examples are shown in
Figure 4 for an ex-smoker with mild
COPD and another with GOLD III
COPD. The spatial relationship between
ventilation defects and PRM gas trapping is more obvious in the ex-smoker
with mild disease, whereas colocalization of PRM emphysema and ventilation

defects are present in the ex-smoker
with severe airflow limitation.
To explore these relationships in
more detail, we quantitatively evaluated the spatial overlap of PRM gas
trapping and emphysema voxels with
ADC and ventilation defects (Table 5,
Fig 5). As shown in Figure 5, 3He
ADC was significantly elevated in areas
of PRM gas trapping compared with
healthy tissue (P = .004 in a healthy exsmoker, P = .01 in patients with GOLD
I and GOLD II disease, P = .03 in a patient with GOLD III/IV disease). Helium
3 ADC values were also significantly
greater in the regions of PRM emphysema compared with regions of PRM
gas trapping in patient with GOLD I
disease (P = .03), but not in healthy
ex-smokers or those with GOLD II, III,
or IV disease. Table 5 shows that, in
mild and moderate COPD, the MR imaging spatial overlap coefficient (SOC)
for 3He ventilation defects with PRM
gas trapping tissue (MR imaging SOC =
36% 6 28 and MR imaging SOC = 34%
6 28 in those with mild and moderate
disease, respectively) was significantly
greater than for PRM emphysema
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Figure 2

Figure 2: 3He MR imaging ventilation and PRM measurements by COPD grade. A, Box plot shows 3He MR imaging VDP in
ex-smokers without COPD (8% 6 4) and with GOLD I (11% 6 6), GOLD II (20% 6 11), and GOLD III/IV (37% 6 9) disease.
There was a significant difference in VDP between ex-smokers without COPD and those with GOLD II disease (P , .001),
ex-smokers without COPD and those with GOLD III/IV disease (P , .001), those with GOLD I and GOLD II disease (P = .04),
those with GOLD II and GOLD III/IV disease (P , .001), and those with GOLD I and GOLD III/IV disease (P , .001). B, Box
plot shows PRM-derived gas-trapping voxels in ex-smokers without COPD (13% 6 10) and ex-smokers with GOLD I (31%
6 11), GOLD II (27% 6 14), and GOLD III/IV (41% 6 8) disease. There is a significant difference in PRM gas trapping
between ex-smokers without COPD and those with GOLD I disease (P , .001), ex-smokers without COPD and those with
GOLD II disease (P = .003), and ex-smokers without COPD and those with GOLD III/IV disease (P , .001). C, Box plot shows
3
He MR imaging ADC values in ex-smokers without COPD (0.29 cm2/s 6 0.08) and those with GOLD I (0.34 cm2/s 6 0.03),
GOLD II (0.36 cm2/s 6 0.06), and GOLD III/IV (0.41 cm2/s 6 0.05) disease. There is a significant difference in ADC values
between ex-smokers without COPD and those with GOLD II disease (P = .02), ex-smokers without COPD and those with
GOLD III/IV disease (P , .001), and those with GOLD I and GOLD III/IV disease (P = .04). D, Box plot shows PRM-derived
emphysema voxels in ex-smokers without COPD (0.5% 6 0.5) and those with GOLD I (3% 6 3), GOLD II (8% 6 11), and
GOLD III/IV (13% 6 12) disease. There is a significant difference in PRM emphysema between ex-smokers without COPD
and those with GOLD II disease (P = .009), ex-smokers without COPD and those with GOLD III/IV disease (P = .001), and
those with GOLD I and GOLD III/IV disease (P = .03). Significant differences between subgroups (P , .05) were determined
with analysis of variance and post hoc Tukey analysis. Error bars = standard deviation.

voxels (mild: MR imaging SOC 1% 6
2, P = .001, and MR imaging SOC = 7%
6 15, P = .006, in those with mild and
moderate disease, respectively). Thus,
in patients with mild and moderate
COPD, 3He ventilation defects showed
a greater spatial relationship with PRM
gas trapping versus emphysema voxels.
Radiology: Volume 279: Number 2—May 2016
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In patients with severe COPD, the CT
SOC for 3He ventilation defects with
PRM emphysema (CT SOC = 64% 6
30) was significantly greater than that
for PRM gas trapping voxels (CT SOC
= 36% 6 18; P = .01). Therefore, for
patients with severe COPD, PRM emphysema was mainly localized within
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regions of 3He ventilation defects. In
addition, in patients with severe COPD,
MR imaging SOC for 3He ventilation
defects with PRM gas trapping voxels
(SOC = 62% 6 25) was significantly
greater than that for PRM emphysema
(SOC = 11% 6 20, P = .009). Hence, in
patients with severe COPD, regions of
603
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Table 3
Pearson Correlations for PRM Gas Trapping and Emphysema Measurements
PRM Gas Trapping
Variable
‡

FEV1
FEV1/FVC (%)
DLCO‡
ADC (cm2/sec)
6G (%)
VDP (%)

Healthy
Ex-Smokers*
20.09
20.33
20.06
0.08
20.16
0.13

PRM Emphysema

P Value

Ex-Smokers
with COPD†

.9
.6
.8
.9
.9
.9

20.29
20.58
20.36
0.53
20.44
0.47

P Value

Healthy
Ex-Smokers*

P Value

Ex-Smokers
with COPD†

P Value

.1
.003
.09
.01
.07
.03

20.11
20.34
20.21
0.30
20.22
0.10

.9
.6
.9
.8
.9
.7

20.43
20.52
20.69
0.69
20.14
0.62

.03
.008
,.001
,.001
.4
,.001

Note.—Unless otherwise indicated, data are Pearson correlation coefficients. P values were determined with Holm-Bonferroni correction. Data were adjusted for age, sex, height, weight, and smoking
history. P = .15 indicates a significant difference. 6G = sixth-generation airway wall area percent.
* n = 26.
†

n = 32.

‡

Percent of predicted value.

Table 4
Multivariate Regressions for PRM Gas Trapping and Emphysema Measurements
PRM Gas Trapping
Variable
FEV1*
FEV1/FVC (%)
DLCO*
ADC (cm2/sec)
6G (%)
VDP (%)

bU

bS

Partial R

…
20.65
…
…
21.72
…

…
20.69
…
…
20.22
…

…
0.53
…
…
0.08
…

PRM Emphysema
2

P Value

bU

bS

Partial R 2

P Value

…
.001
…
…
.02
…

…
…
20.10
…
…
0.29

…
…
20.29
…
…
0.41

…
…
0.10
…
…
0.20

…
…
.03
…
…
.001

Note.—Unless otherwise indicated, data are Pearson correlation coefficients. P values were determined with Holm-Bonferroni correction. Data were adjusted for age, sex, height, weight, and smoking
history. P = .15 indicates a significant difference. n = 58. 6G = sixth-generation airway, bU = unstandardized regression coefficient, bS = standardized regression coefficient.
* Percent of predicted value.

3

He ventilation defects mostly consisted
of PRM gas trapping voxels, although
there was a mixture of PRM gas trapping and emphysema.

Discussion
We evaluated 58 ex-smokers in the
first direct comparison of PRM and
MR imaging measurements of COPD.
We acquired inspiration and expiration CT images and noble gas MR images within 1 hour and observed the
following findings: (a) with increasing
severity of airflow limitation, PRM gas
trapping, PRM emphysema, ADC, and
VDP measurements were significantly
greater; (b) 3He ventilation and PRM
measurements were correlated in
604

COPD but not in healthy ex-smokers;
(c) in a multivariate model that predicted PRM gas trapping, wall area
percent and FEV1/FVC were significant, whereas VDP and DLCO were significant for PRM emphysema; and (d)
3
He ADC values were significantly elevated in regions of PRM gas trapping,
and there were quantitative and spatial
correlations for both PRM gas trapping and emphysema with 3He ventilation defects that differed according to
COPD severity.
PRMs are used to classify lung tissue on the basis of the presence of pulmonary air, either as a consequence of
emphysema and gas trapping from airways disease and/or emphysema (9).
We were curious about the potential

relationships between PRM and MR imaging phenotypes of COPD, especially
because both ventilation defects and
PRM gas trapping have been suggested
as biomarkers of small airways disease.
First, we observed that, with increasing
severity of airflow limitation, PRM gas
trapping, PRM emphysema, ADC, and
VDP measurements were significantly
greater. We also noted that 3He VDP
and PRM measurements were correlated in ex-smokers with COPD but not
in ex-smokers with normal pulmonary
function. This finding might be expected
because correlations in ex-smokers with
mainly normal pulmonary function are
statistically difficult to ascertain in small
sample sizes, since the range of values
for normal lung function is small (31). It
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Figure 3

Figure 3: Relationships between 3He MR imaging VDP and ADC with PRM-derived gas-trapping and PRM emphysema voxels. A, Scatter plot shows linear
regression for 3He MR imaging VDP with PRM in all subjects (gas-trapping voxels: r = 0.58, r 2 = 0.34, P , .001, y = 0.73x 2 12.88; emphysema voxels: r =
0.68, r 2 = 0.47, P , .001, y = 0.47x 2 2.78), ex-smokers without COPD (gas-trapping voxels: r = 0.13, r 2 = 0.02, P = .9, y = 0.35x + 10.92; emphysema
voxels: r = 0.10, r 2 = 0.009, P = .7, y = 0.01x + 0.39), and ex-smokers with COPD (gas-trapping voxels: r = 0.47, r 2 = 0.23, P = .03, y = 0.46x + 22.12;
emphysema voxels: r = 0.62, r 2 = 0.38, P , .001, y = 0.46x 2 2.22). B, Scatter plot shows linear regression for 3He MR imaging ADC with PRM in all subjects
(gas-trapping voxels: r = 0.55, r 2 = 0.30, P , .001, y = 122x 2 17; emphysema voxels: r = 0.62, r 2 = 0.39, P , .001, y = 77x 2 22), ex-smokers without
COPD (gas-trapping voxels: r = 0.08, r 2 = 0.006, P = .9, y = 14x + 10; emphysema voxels: r = 0.30, r 2 = 0.09, P = .8, y = 2.5x 2 0.3), and ex-smokers with
COPD (gas-trapping voxels: r = 0.53, r 2 = 0.28, P = .01, y = 119x 2 12; emphysema voxels: r = 0.69, r 2 = 0.48, P , .001, y = 121x 2 37). C, Bland-Altman
plot shows analysis of agreement for 3He MR imaging VDP and PRM in all subjects (gas-trapping voxels: bias = 29% 6 12, lower limit = 232%, upper limit =
15%; emphysema voxels: bias = 11% 6 9, lower limit = 26%, upper limit = 28%), ex-smokers without COPD (gas-trapping voxels: bias = 26% 6 10, lower
limit = 226%, upper limit = 15%; emphysema voxels: bias = 8% 6 4, lower limit = 1%, upper limit = 15%), and ex-smokers with COPD (gas-trapping voxels:
bias = 211% 6 13, lower limit = 236%, upper limit = 14%; emphysema voxels: bias = 13% 6 10, lower limit = 27%, upper limit = 33%). Dotted lines =
95% confidence intervals.

is also worth noting that, in this study,
CT emphysema measurements for
healthy ex-smokers were in agreement
with previously reported values for
healthy subjects (7,32). Importantly, CT
may not be adequately sensitive to very
mild or subclinical parenchymal and obstructive disease; this may also partially
explain the negligible VDP and PRM correlations in healthy ex-smokers (33).
In addition to these bilateral relationships, multivariate modeling identified the parameters that significantly
added to the model for PRM gas trapping (wall area percent and FEV1/FVC)
and PRM emphysema (VDP and DLCO).
The PRM gas trapping model is intuitive and was developed on the basis of
our previous knowledge of the role of
airway wall morphologic characteristics in functional small airways disease
(34). This finding is also consistent
with the major pulmonary imaging and
clinical phenotypes that were recently
summarized by the Fleischner Society
Radiology: Volume 279: Number 2—May 2016
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(35). However, we note that, while
the significant contribution of DLCO
to PRM emphysema is also consistent
with a large body of previous work, the
contribution of PRM emphysema to
ventilation defects is a novel and somewhat surprising result (36). Strong
hints that ventilation defects may stem
from emphysematous bullae were previously reported in patients with advanced or severe COPD and numerous
exacerbations that required hospitalization (22). Together, this information
suggests a role for pulmonary imaging
to phenotype COPD beyond FEV1 to
help guide therapy and change exacerbations and other outcomes.
These quantitative associations
and some obvious qualitative regional
relationships led to our exploration of
potential spatial correlations. Notably
(and unexpectedly), we observed that
3
He ADC values were significantly elevated in regions of PRM gas trapping.
This surprising result suggested that
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PRM functional small-airway disease
that leads to gas trapping may be seen
as enlarged airs paces, which is reflected by elevated ADC values. This
is one of the first studies to spatially
compare 3He ADC to gas-trapping
measurements. This novel finding is in
agreement with other studies that demonstrated gravitational and lung volume
effects on pulmonary ADC values (39–
39). This also suggests that abnormally
elevated ADC values may not always reflect emphysematous abnormalities in
patients with COPD. There were also
spatial correlations in patients with
mild and moderate COPD, in whom
3
He MR imaging ventilation defects
were spatially related to PRM gas trapping. In contrast, in the small group of
seven patients with severe COPD, MR
imaging ventilation defects were spatially related to both PRM gas trapping
and emphysema, which were identified
with CT and MR imaging SOC. The rationale for performing SOC analysis in
605
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Figure 4

Figure 4: Spatial relationship of 3He MR imaging ventilation defects with PRM gas trapping and emphysema. 3He MR images coregistered with 1H MR imaging and CT obtained in, A, a 69-year-old man with mild
COPD (GOLD I; FEV1, 89% of predicted value; FEV1/FVC, 69%; RV/TLC, 39 FEV1%, DLCO, 67% of predicted
value) and, B, a 78-year-old man with severe COPD (GOLD III; 47% of predicted value; FEV1/FVC, 37%;
RV/TLC, 50%; DLCO, 57% of predicted value) show 3He MR imaging ventilation (blue), PRM healthy tissue
(green), PRM gas trapping (yellow), and PRM emphysema (red), as well as the spatial relationship between
ventilation defects with regions of PRM gas trapping and emphysema (arrows).

both directions was the need to evaluate the overlap of 3He defects within
PRM regions (CT SOC) and the overlap
of PRM voxels within 3He defects (MR
imaging SOC). While the quantitative results showed differences between the two
606

methods, this was not a result of asymmetry between registering from the fixed
to the moving image because we performed registration in a symmetric manner to mitigate this potential bias (40,41).
It was important to perform the spatial

overlap analysis in both directions because the results showed that, in severe
COPD, PRM emphysema voxels were
mainly occupied by ventilation defect
voxels. In contrast, ventilation defect
voxels were mainly occupied by PRM
gas-trapping voxels. This means that
both PRM emphysema and gas-trapping voxels are spatially coincident with
ventilation defects. This exciting result
provides, for the first time, a deeper
understanding of the source of ventilation defects and gas trapping in COPD.
We think that these findings underscore
the importance of phenotyping COPD
cases with quantitative imaging. Future
work should aim to determine the spatial relationships between continuous
pixel-wise data and PRM, as this may
provide a better understanding of these
relationships.
Numerous studies have used paired
inspiratory and expiratory lung CT
images to provide COPD phenotypes
(42–44). In patients with COPD, gas
trapping is influenced by both emphysema and small-airways disease,
differentiation of which is attempted
with PRM (43,45). In addition, severe
small-airways disease sometimes appears at CT as emphysema, making it
challenging to delineate between the
two phenotypes. Regardless, in this
study, we determined the different relationships between MR imaging and
CT phenotypes of COPD cases across
GOLD grades of severity. We think
that these results underscore the need
to adopt multimodality approaches to
deeply phenotype COPD cases so that
the independent contributions of emphysema and airways disease may be
ascertained, which may help optimize
COPD therapy and improve outcomes.
In summary, in all ex-smokers,
ventilation defects and ADC values
were correlated with PRM gas trapping and emphysema measurements.
In a subset of ex-smokers with mild to
moderate COPD, ventilation defects
were quantitatively and spatially related to PRM gas trapping, whereas in
severe COPD, there were spatial and
quantitative relationships for ventilation defects with both PRM gas trapping and emphysema.
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Table 5
Quantitative Spatial Relationships for 3He MR imaging Ventilation Defects with CT PRM Voxels
Ex-Smokers with COPD

Healthy Ex-Smokers
(n = 26)

Characteristic
Gas trapping to VDP (%)
Emphysema to VDP (%)
Significant difference*

3 6 12
060
0.2

VDP to gas trapping (%)
VDP to emphysema (%)
Significant difference*

368
060
0.09

All (n = 32)

GOLD I (n = 12)

GOLD II (n = 13)

Spatial Overlap Coefficient Normalized with CT Voxels
15 6 16
464
13 6 13
22 6 32
369
16 6 27
0.06
0.5
0.5
Spatial Overlap Coefficient Normalized with MR Imaging Voxels
41 6 29
36 6 28
34 6 28
6 6 14
162
7 6 15
,0.001
0.001
0.006

GOLD III/IV (n = 7)

P Value

36 6 18
64 6 30
0.01

,.001
,.001
…

62 6 25
11 6 20
0.009

,.001
.04
…

Note.—Unless otherwise indicated, data are mean plus or minus standard deviation. P values were determined with analysis of variance and Tukey correction; P , .05 indicates a significant difference.
*Significant difference was measured with paired t test for spatial overlap coefficients of MR imaging ventilation defects with PRM gas trapping and emphysema.

disease: GOLD executive summary. Am J
Respir Crit Care Med 2013;187(4):347–365.

Figure 5

2. Hackx M, Bankier AA, Gevenois PA. Chronic
obstructive pulmonary disease: CT quantification of airways disease. Radiology 2012;
265(1):34–48.
3. Nakano Y, Müller NL, King GG, et al. Quantitative assessment of airway remodeling
using high-resolution CT. Chest 2002;122(6
Suppl):271S–275S.
4. Hayhurst MD, MacNee W, Flenley DC, et al.
Diagnosis of pulmonary emphysema by computerised tomography. Lancet 1984;2(8398):
320–322.

Figure 5: Spatial 3He MR imaging ADC measurements within PRM regions
of healthy, gas-trapped, and emphysematous tissue. Box plot shows 3He ADC
measurements in PRM regions of healthy tissue (ex-smokers without COPD,
0.27 cm2/sec 6 0.05 and ex-smokers with GOLD I, 0.34 cm2/sec 6 0.03;
GOLD II, 0.36 cm2/sec 6 0.09; and GOLD III/IV disease , 0.41 cm2/sec 6
0.07), gas trapping (ex-smokers without COPD, 0.28 cm2/sec 6 0.05 and
ex-smokers with GOLD II, 0.35 cm2/sec 6 0.04, GOLD II, 0.38 cm2/sec 6
0.11; and GOLD III/IV disease, 0.44 cm2/sec 6 0.08), and emphysema (exsmokers without COPD, 0.29 cm2/sec 6 0.06 and ex-smokers with GOLD
I, 0.36 cm2/sec 6 0.05; GOLD II, 0.39 cm2/sec 6 0.12; and GOLD III/IV
disease, 0.46 cm2/sec 6 0.10). Error bars = standard deviation.
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